204 related articles for article (PubMed ID: 31605778)
1. Hypothalamic orexin and mechanistic target of rapamycin activation mediate sleep dysfunction in a mouse model of tuberous sclerosis complex.
Zhang B; Guo D; Han L; Rensing N; Satoh A; Wong M
Neurobiol Dis; 2020 Feb; 134():104615. PubMed ID: 31605778
[TBL] [Abstract][Full Text] [Related]
2. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
[TBL] [Abstract][Full Text] [Related]
3. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
Rensing N; Han L; Wong M
Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.
Zeng LH; Xu L; Gutmann DH; Wong M
Ann Neurol; 2008 Apr; 63(4):444-53. PubMed ID: 18389497
[TBL] [Abstract][Full Text] [Related]
5. Cerebral vascular and blood brain-barrier abnormalities in a mouse model of epilepsy and tuberous sclerosis complex.
Guo D; Zhang B; Han L; Rensing NR; Wong M
Epilepsia; 2024 Feb; 65(2):483-496. PubMed ID: 38049961
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex.
Zhang B; Zou J; Rensing NR; Yang M; Wong M
Neurobiol Dis; 2015 Aug; 80():70-9. PubMed ID: 26003087
[TBL] [Abstract][Full Text] [Related]
7. Epileptogenesis and reduced inward rectifier potassium current in tuberous sclerosis complex-1-deficient astrocytes.
Jansen LA; Uhlmann EJ; Crino PB; Gutmann DH; Wong M
Epilepsia; 2005 Dec; 46(12):1871-80. PubMed ID: 16393152
[TBL] [Abstract][Full Text] [Related]
8. Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an age-dependent manner.
Zou J; Zhang B; Gutmann DH; Wong M
Epilepsia; 2017 Dec; 58(12):2053-2063. PubMed ID: 29023667
[TBL] [Abstract][Full Text] [Related]
9. The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex.
Zhang B; Zou J; Han L; Beeler B; Friedman JL; Griffin E; Piao YS; Rensing NR; Wong M
Epilepsia; 2018 Sep; 59(9):1796-1806. PubMed ID: 30079598
[TBL] [Abstract][Full Text] [Related]
10. Microglial activation during epileptogenesis in a mouse model of tuberous sclerosis complex.
Zhang B; Zou J; Han L; Rensing N; Wong M
Epilepsia; 2016 Aug; 57(8):1317-25. PubMed ID: 27263494
[TBL] [Abstract][Full Text] [Related]
11. Early developmental electroencephalography abnormalities, neonatal seizures, and induced spasms in a mouse model of tuberous sclerosis complex.
Rensing N; Johnson KJ; Foutz TJ; Friedman JL; Galindo R; Wong M
Epilepsia; 2020 May; 61(5):879-891. PubMed ID: 32274803
[TBL] [Abstract][Full Text] [Related]
12. The natural history and treatment of epilepsy in a murine model of tuberous sclerosis.
Erbayat-Altay E; Zeng LH; Xu L; Gutmann DH; Wong M
Epilepsia; 2007 Aug; 48(8):1470-6. PubMed ID: 17484760
[TBL] [Abstract][Full Text] [Related]
13. Impaired astrocytic gap junction coupling and potassium buffering in a mouse model of tuberous sclerosis complex.
Xu L; Zeng LH; Wong M
Neurobiol Dis; 2009 May; 34(2):291-9. PubMed ID: 19385061
[TBL] [Abstract][Full Text] [Related]
14. Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex.
Carson RP; Fu C; Winzenburger P; Ess KC
Hum Mol Genet; 2013 Jan; 22(1):140-52. PubMed ID: 23049074
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Proteostasis of BMAL1 Underlies Circadian Abnormalities in a Paradigmatic mTOR-opathy.
Lipton JO; Boyle LM; Yuan ED; Hochstrasser KJ; Chifamba FF; Nathan A; Tsai PT; Davis F; Sahin M
Cell Rep; 2017 Jul; 20(4):868-880. PubMed ID: 28746872
[TBL] [Abstract][Full Text] [Related]
17. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
Nguyen LH; Mahadeo T; Bordey A
J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
[TBL] [Abstract][Full Text] [Related]
18. Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex.
Zeng LH; Ouyang Y; Gazit V; Cirrito JR; Jansen LA; Ess KC; Yamada KA; Wozniak DF; Holtzman DM; Gutmann DH; Wong M
Neurobiol Dis; 2007 Nov; 28(2):184-96. PubMed ID: 17714952
[TBL] [Abstract][Full Text] [Related]
19. Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex.
Zeng LH; Bero AW; Zhang B; Holtzman DM; Wong M
Neurobiol Dis; 2010 Mar; 37(3):764-71. PubMed ID: 20045054
[TBL] [Abstract][Full Text] [Related]
20. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex.
Theilmann W; Gericke B; Schidlitzki A; Muneeb Anjum SM; Borsdorf S; Harries T; Roberds SL; Aguiar DJ; Brunner D; Leiser SC; Song D; Fabbro D; Hillmann P; Wymann MP; Löscher W
Neuropharmacology; 2020 Dec; 180():108297. PubMed ID: 32890589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
